Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

heart attack patients

Deal Watch December 2016

Allergan, AZ, BMS, Pfizer, Roche and more feature in this month's pharma deals round-up

AstraZeneca AZ

AZ tweaks immuno-oncology trials as it chases lung cancer leaders

Toughens targets for durvalumab in NSCLC monotherapy and combination study

- PMLiVE

NICE U-turn on Novartis’ Afinitor for kidney cancer

Set to back treatment's routine NHS use following offer of discount and new data

- PMLiVE

Merck & Co’s Keytruda muscles further ahead of rivals in lung cancer

Granted accelerated review by FDA for use in combination with chemotherapy

- PMLiVE

AstraZeneca appoints head of oncology

Dr Jamie Freedman joins from AZ subsidiary MedImmune

National Institute for Health and Care Excellence NICE logo

NICE recognises Smartinhaler as best practice for asthma care

Digital monitoring device proven to increase adherence and reduce hospital visits

- PMLiVE

Wales unveils ‘sensible’ £80m medicines access fund

New scheme hopes to provide greater consistency and accelerate availability by eight weeks

- PMLiVE

FDA okays Clovis’ Lynparza rival rucaparib

Analysts predict Rubraca could become a $1.5bn-plus product by 2020

Eli Lilly HQ

Lilly taps AstraZeneca for another anti-amyloid drug

MEDI1814 could potentially slow the progression of Alzheimer's

- PMLiVE

AZ’s Tagrisso beats chemotherapy in lung cancer trial

Phase III data shows greater progression-free survival in mutation-positive NSCLC patients

AstraZeneca AZ

AZ signs $1bn deal with Bicycle Therapeutics

Eyes broad range of applications for the firm’s peptide technology

- PMLiVE

AstraZeneca’s John Rex joins UK biotech F2G

Takes up the role of chief medical officer at the UK company

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links